These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 38750040)
21. Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation. Chapman PB Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714462 [TBL] [Abstract][Full Text] [Related]
22. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib. Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875 [TBL] [Abstract][Full Text] [Related]
23. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E. Cheng L; Jin Y; Liu M; Ruan M; Chen L Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638 [TBL] [Abstract][Full Text] [Related]
24. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. Johnson AS; Crandall H; Dahlman K; Kelley MC J Am Coll Surg; 2015 Apr; 220(4):581-93.e1. PubMed ID: 25797743 [TBL] [Abstract][Full Text] [Related]
26. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524 [TBL] [Abstract][Full Text] [Related]
29. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma. Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478 [TBL] [Abstract][Full Text] [Related]
30. Dabrafenib and trametinib in BRAFV600E mutated glioma. Brown NF; Carter T; Kitchen N; Mulholland P CNS Oncol; 2017 Oct; 6(4):291-296. PubMed ID: 28984141 [TBL] [Abstract][Full Text] [Related]
31. Early response in phosphorylation of ribosomal protein S6 is associated with sensitivity to trametinib in colorectal cancer cells. Hirashita Y; Tsukamoto Y; Kudo Y; Kakisako D; Kurogi S; Hijiya N; Nakada C; Uchida T; Hirashita T; Hiratsuka T; Akagi T; Ueda Y; Shiroshita H; Etoh T; Mizukami K; Honda K; Okimoto T; Kodama M; Inomata M; Moriyama M; Murakami K Lab Invest; 2021 Aug; 101(8):1036-1047. PubMed ID: 33911189 [TBL] [Abstract][Full Text] [Related]
32. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Lassen A; Atefi M; Robert L; Wong DJ; Cerniglia M; Comin-Anduix B; Ribas A Mol Cancer; 2014 Apr; 13():83. PubMed ID: 24735930 [TBL] [Abstract][Full Text] [Related]
33. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Vella LJ; Pasam A; Dimopoulos N; Andrews M; Knights A; Puaux AL; Louahed J; Chen W; Woods K; Cebon JS Cancer Immunol Res; 2014 Apr; 2(4):351-60. PubMed ID: 24764582 [TBL] [Abstract][Full Text] [Related]
34. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Gonzalez-Cao M; Mayo de Las Casas C; Oramas J; Berciano-Guerrero MA; de la Cruz L; Cerezuela P; Arance A; Muñoz-Couselo E; Espinosa E; Puertolas T; Diaz Beveridge R; Ochenduszko S; Villanueva MJ; Basterretxea L; Bellido L; Rodriguez D; Campos B; Montagut C; Drozdowskyj A; Molina MA; Lopez-Martin JA; Berrocal A Nat Commun; 2021 Dec; 12(1):7008. PubMed ID: 34853302 [TBL] [Abstract][Full Text] [Related]
35. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
36. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. von Euw E; Atefi M; Attar N; Chu C; Zachariah S; Burgess BL; Mok S; Ng C; Wong DJ; Chmielowski B; Lichter DI; Koya RC; McCannel TA; Izmailova E; Ribas A Mol Cancer; 2012 Apr; 11():22. PubMed ID: 22515704 [TBL] [Abstract][Full Text] [Related]
37. "RB-reactivator screening" as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist). Sakai T Pharmacol Ther; 2022 Aug; 236():108234. PubMed ID: 35732246 [TBL] [Abstract][Full Text] [Related]
38. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers. Dai X; Xia H; Zhou S; Tang Q; Bi F Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107 [TBL] [Abstract][Full Text] [Related]